Creso Pharma (ASX: CPH) has released an update on commercialisation of their CBD food supplements, showing increasing growth both of sales and products lines.
Their two human health products, cannaQIX® 10 and 50 in Human Health are said to be progressing steadily and generating revenues, with substantial progress achieved with commercial partners Doetsch Grether Switzerland and Pharmacare UK. Through these partnerships, Creso’s products are achieving significant penetration into pharmacies and drug stores.
Creso’s range for pets, ‘anibidiol’, has had a successful launch in Switzerland and will be distributed in an additional 14 countries this year.
They are also launching a number of additional products for stress, sleep, pain and general wellbeing, along with a line of medicinal cannabis products out of Creso’s Canadia cultivation facility.
Dr. Miri Halperin Wernli, Creso’s CEO and Co-Founder said, “All our premium products will be introduced globally, as we seek to meet growing demand and advance the availability and development of alternative health and wellness solutions. One of Creso’s strongest capabilities is our therapeutic science. We combine our own expertise with contributions from world-class biomedical scientists, clinical researchers and medical professionals. We know how chemicals and human chemistry interact, and we are passionate about utilizing hemp and cannabis plant ingredients to deliver the most benefit to humans and animals, everywhere.”